298 related articles for article (PubMed ID: 15690716)
21. Pure red cell aplasia secondary to treatment with erythropoietin.
Locatelli F; Del Vecchio L
J Nephrol; 2003; 16(4):461-6. PubMed ID: 14696747
[TBL] [Abstract][Full Text] [Related]
22. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
Casadevall N; Nataf J; Viron B; Kolta A; Kiladjian JJ; Martin-Dupont P; Michaud P; Papo T; Ugo V; Teyssandier I; Varet B; Mayeux P
N Engl J Med; 2002 Feb; 346(7):469-75. PubMed ID: 11844847
[TBL] [Abstract][Full Text] [Related]
23. Prolonged course of pure red cell aplasia after erythropoietin therapy.
Nigg L; Schanz U; Ambühl PM; Fehr J; Bachli EB
Eur J Haematol; 2004 Nov; 73(5):376-9. PubMed ID: 15458518
[TBL] [Abstract][Full Text] [Related]
24. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin.
Shimizu H; Saitoh T; Ota F; Jimbo T; Tsukada Y; Murakami H; Nojima Y
Acta Haematol; 2011; 126(2):114-8. PubMed ID: 21654161
[TBL] [Abstract][Full Text] [Related]
25. [Diagnosis and treatment of pure red-cell aplasia induced by erythropoiesis stimulating agents].
Rossert J; Casadevall N
Nephrol Ther; 2006 Sep; 2 Suppl 4():S283-6. PubMed ID: 17373271
[TBL] [Abstract][Full Text] [Related]
26. Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia.
Mandreoli M; Finelli C; Lopez A; Ascani S; Vianelli N; Baccarani M; Santoro A
Am J Kidney Dis; 2004 Oct; 44(4):757-61. PubMed ID: 15384028
[TBL] [Abstract][Full Text] [Related]
27. A clinical review of antibody-mediated pure red cell aplasia.
Vogel S; Rossert J
Nephrol Nurs J; 2005; 32(1):17-8, 23-6; quiz 27. PubMed ID: 15787081
[TBL] [Abstract][Full Text] [Related]
28. Erythropoietin and renal failure.
Macdougall IC
Curr Hematol Rep; 2003 Nov; 2(6):459-64. PubMed ID: 14561389
[TBL] [Abstract][Full Text] [Related]
29. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery.
Boven K; Knight J; Bader F; Rossert J; Eckardt KU; Casadevall N
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii33-40. PubMed ID: 15824129
[TBL] [Abstract][Full Text] [Related]
30. Optimizing anaemia management with subcutaneous administration of epoetin.
Besarab A
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi10-5. PubMed ID: 15958820
[TBL] [Abstract][Full Text] [Related]
31. Two haemodialysis patients with epoetin alfa-induced pure red-cell aplasia recovered despite treatment with another epoetin preparation.
Vartia A; Asola MR; Tertti R; Kunelius P; Metsärinne KP
Nephrol Dial Transplant; 2004 May; 19(5):1313-6. PubMed ID: 15102972
[No Abstract] [Full Text] [Related]
32. [Pure red cell aplasia developed during treatment with erythropoietin. Complete remission during immunosuppressive therapy].
Høi-Hansen T; Lauritzen AM; Hansen PB
Ugeskr Laeger; 2003 May; 165(19):2001-2. PubMed ID: 12795077
[TBL] [Abstract][Full Text] [Related]
33. [Possible complications of erythropoietin therapy in patients with chronic renal failure].
Pljesa S
Med Pregl; 2004; 57(5-6):254-7. PubMed ID: 15503795
[TBL] [Abstract][Full Text] [Related]
34. Drug-induced autoimmune red-cell aplasia.
Bunn HF
N Engl J Med; 2002 Feb; 346(7):522-3. PubMed ID: 11844855
[No Abstract] [Full Text] [Related]
35. Importance of biologic follow-ons: experience with EPO.
Casadevall N; Rossert J
Best Pract Res Clin Haematol; 2005; 18(3):381-7. PubMed ID: 15792912
[TBL] [Abstract][Full Text] [Related]
36. [Early onset of anti- erythropoietin antibody-mediated pure red cell aplasia after commencement of subcutaneous administration of epoetin-β].
Tanaka A; Tsukada J; Morimoto H; Katsuragi T; Nakanishi T; Watanabe S; Hirase N; Motomura S
Rinsho Ketsueki; 2012 Jan; 53(1):110-2. PubMed ID: 22374534
[TBL] [Abstract][Full Text] [Related]
37. High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases.
Schönholzer C; Keusch G; Nigg L; Robert D; Wauters JP
Nephrol Dial Transplant; 2004 Aug; 19(8):2121-5. PubMed ID: 15252171
[TBL] [Abstract][Full Text] [Related]
38. Intravenous versus subcutaneous EPO: anything to do with pure red cell aplasia complication.
Chow KM; Szeto CC; Li PK
Am J Kidney Dis; 2003 Jan; 41(1):266-7; author reply 267. PubMed ID: 12500250
[No Abstract] [Full Text] [Related]
39. Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge.
Smalling R; Foote M; Molineux G; Swanson SJ; Elliott S
Biotechnol Annu Rev; 2004; 10():237-50. PubMed ID: 15504708
[TBL] [Abstract][Full Text] [Related]
40. Successful corticosteroid therapy for epoetin-beta-induced pure red-cell aplasia in a hemodialysis patient.
Zerbi S; Cozzi G; Mercieri A; Faranna P; Ruggiero P; Pedrini LA
Am J Hematol; 2006 Oct; 81(10):803-4. PubMed ID: 16783786
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
